Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Yeungnam Med Sci > Volume 32(2); 2015 > Article
Case Report Secondary amyloidosis complication of Crohn disease treated with infliximab.
Min Joo Song, Hyo Sang Kim, Soyoung Park, Jaekyung Cheon, Sojung Park, Ji Young Yang, Su Kil Park
Journal of Yeungnam Medical Science 2015;32(2):102-105
DOI: https://doi.org/10.12701/yujm.2015.32.2.102
Published online: December 31, 2015
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. skpark@amc.seoul.kr
  • 1,887 Views
  • 6 Download
  • 0 Crossref
  • 0 Scopus

Secondary systemic (AA) amyloidosis is a severe complication of progressed Crohn disease (CD) characterized by the deposition of amyloid A in body organs and tissues. Various therapeutic approaches have been recommended, however there is still no effective treatment. Recently, several case reports have demonstrated the effects of anti-tumor necrosis factor-alpha therapy in patients with AA amyloidosis associated with CD. We report on a 35-year-old female patient with CD complicated by AA amyloidosis in the gastrointestinal tract and renal involvement, who was treated with infliximab. The infliximab therapy improved the gastrointestinal symptoms and decreased the serum creatinine.

Related articles

JYMS : Journal of Yeungnam Medical Science